Dr. Andrew Kraftson regarding Eli Lilly’s new direct-to-consumer platform for its Zepbound weight loss drug.

Cardiology Pharmaceuticals

Applied Therapeutics’ AT-001 Trial Misses Mark

Applied Therapeutics saw its shares fall 40% late last week after revealing that its diabetic cardiomyopathy drug candidate AT-001 (caficrestat) didn’t meet its phase 3 trial’s primary endpoint. However, the trial did show enough “encouraging results” for Applied to assert that AT-001 could still become the first diabetic cardiomyopathy treatment.

• Diabetic cardiomyopathy (DbCM) describes diabetes-associated changes in the structure and function of the heart’s myocardium, often leading to heart failure. 
• AT-001 is an investigational oral Aldose Reductase inhibitor being developed for the treatment of diabetic cardiomyopathy.
• There are no other drugs specifically approved to treat DbCM, although some patients are prescribed SGLT2 inhibitors

The ARISE-HF phase 3 trial had 675 DbCM patients at high risk of progression to overt heart failure take either AT-001 or a placebo, as an add-on to standard diabetes therapies.

The study didn’t show statistically significant improvements or prevention of worsening DbCM (the primary endpoint) — the AT-001 and placebo groups had -0.01 and -0.31 ml/kg/min Peak VO2 declines over 15 months (p = 0.210).

However, there was some secondary silver linings:

• AT-001 achieved statistically significant improvements among the 62% of participants who weren’t also taking SGLT2 or GLP-1 inhibitors (+0.08 vs. -0.54 ml/kg/min Peak VO2).
• Far fewer participants in the AT-001 group experienced “clinically significant worsening in cardiac functional capacity” than the placebo group (32.7% vs. 46%).
• AT-001 was generally safe and well tolerated, as both groups had similar rates of serious adverse events and low incidence of treatment-related discontinuations.

These secondary outcomes were enough for Applied Therapeutics to call its results “encouraging” and position AT-001 as an “important potential tool for physicians in treatment of DbCM patients,” especially considering that DbCM patients still don’t have an approved therapy.

However, Applied Therapeutics is apparently more “encouraged”about its galactosemia drug govorestat, announcing plans to find a partner to bring AT-001 to approval and commercialization, so it can focus its resources on govorestat.

The Takeaway
Although most headlines focused on Applied Therapeutics’s stock decline, and some folks on Twitter/X mocked its mention of “encouraging results,” the fact that AT-001 stabilized cardiac functional capacity (especially among those not on SGLT2 or GLP-1 inhibitors) might actually be encouraging for DbCM patients currently living without an approved therapy.

Measuring True Cardiac Risk

How can AI help physicians “see” beyond conventional lipid profiles? Tune in to this on-demand webinar showcasing how Cleerly’s AI-QCT solution complements conventional approaches to evaluating heart disease risk factors, and improves coronary artery disease diagnosis and heart attack risk assessments.

PIA’s Post-Processing Solution

Advanced cardiac imaging often calls for a time-consuming post-processing step, requiring costly software, hardware, and training. See how PIA provides this post-processing at lower cost, improved consistency, and greater efficiency.

Where to Go for Cardio AI?

TeraRecon’s Cardio Suite is a collection of hand-selected, vendor-neutral Cardiology AI algorithms that aid in the analysis and interpretation of echocardiograms and chest CTs. Learn about TeraRecon’s AI offering and how they improve efficiency and accuracy here.

The Wire

• Lilly Goes DTC: Eli Lilly raised eyebrows and concerns across healthcare last week, with the launch of its LillyDirect platform, built to connect patients with an independent telehealth provider that would handle prescribing and delivering its Zepbound GLP-1 obesity med. Although LillyDirect doesn’t offer any financial advantages, it provides convenient access to the drug and should help convert more of Lilly’s web visitors into Zepbound users. Whether it will provide patients with similar care as traditional routes is another story.

• ICE Freezes Conduction Disturbances in TAVR: In a recent JACC: Cardiovascular Interventions study, researchers utilized transjugular intracardiac echocardiography (ICE) during TAVR procedures, reporting a 30-day permanent pacemaker implantation rate of just 0.9%, which is a significant reduction from the 7% and 14.2% rates seen with conventional visualization methods. The novel approach combines the cusp-overlap view with ICE and allows for real-time visualization of the membranous septum, marking a potential paradigm shift for TAVR imaging.

• K Health & Mayo’s ECG AI Alliance: AI-driven primary care company K Health entered into a know-how agreement with Mayo Clinic aimed at developing an AI solution for ECG-based risk assessments, remote patient monitoring, and treatment personalization. K Health has been licensing Mayo’s de-identified patient data to train and refine its AI algorithms since 2020, and the organizations also have plenty of outside co-development experience including Mayo’s recent alliance with Agamon and K Health’s partnership with Cedars-Sinai.

• Cell Therapy and HF Life Quality: Results from the CHART-1 study (N=315) suggest that cardiopoiesis-guided cell therapy improves Quality of Life in some HFrEF patient groups, but not others. MLHFQ scores were similar for patients in both the study’s cell therapy and sham groups. However, among patients with HFrEF and cardiac chamber enlargement, cell therapy improved MLHFQ scores by 6.4 points and reduced death and hospitalization rates.

• HeartFlow’s FFRCT Milestone: HeartFlow had reason to celebrate as it entered 2024, surpassing 250,000 patients examined with its FFRCT Analysis solution, while helping to avoid a huge number of unnecessary invasive angiographies. That milestone brings HeartFlow FFRCT Analysis to a usage level never seen in most healthcare AI segments, and brings the solution closer to HealtFlow’s goal of becoming the “new standard of care” for non-invasive ischemia testing.

• UCL’s ECGI Vest: UCL researchers developed a reusable electrocardiographic imaging (ECGI) vest that maps the heart’s electrical activity in just five minutes, which could lead to a “quick and cost-effective screening tool” to identify patients at greater risk of sudden cardiac death. By combining the vest’s electrical data with cardiac MRI exams, clinicians might also be able to identify the structural causes of electrical abnormalities, allowing for more personalized risk stratification and treatments.

• Private Equity Adverse Events: Private equity firms are back under fire, this time for driving an outsized number of adverse events at the hospitals they acquire. A large JAMA study showed that Medicare patients at hospitals acquired by PE firms went on to experience 25.4% more adverse events within just three years of their acquisition. That surge was driven in part by notable increases in falls (+27.3%), central line-associated bloodstream infections (+37.7%), and surgical site infections (+100%). Check out this Digital Health Wire deep dive for more details.

• Low LDL Testing Post-MI: In a retrospective study of 533k Medicare beneficiaries treated for MI between 2016 and 2020, only 30% received LDL-C testing within 90 days of discharge, suggesting that insufficient action is being taken to ensure cholesterol levels are reduced (as suggested by MI treatment guidelines). As many of you might expect, testing rates varied depending on race, income, and geographic location.

• Vasa’s CV Aging Funding: Preclinical stage biopharma Vasa Therapeutics landed $6M in seed funding and another $2.3M in grants to advance its novel cardiovascular aging therapies. Vasa’s VS-041 could be the first personalized treatment for HFpEF, as it has shown robust reduction of cardiac fibrosis in a preclinical model, and inhibits the release of signaling collagen fragments that drive fibroinflammatory responses. VS-041’s Phase 1 trials are scheduled to begin in Q2 2024.

• Optimizing Diabetes HF Screening: A study of diabetes patients without ASCVD found that performing WATCH-DM score evaluations followed by selective NT-proBNP testing is clinically effective and economical for HF risk screening. In 4,889 diabetic patients without ASCVD, 6.2% developed HF over five years. Many of those patients who developed HF (85%) could be identified using a variety of two-step screening strategies, but performing selective NT-proBNP testing based on initial WATCH-DM risk scores was most cost effective. 

• Questioning LLMs on AFib and CIEDs: Researchers in Germany assessed the leading LLMs’ responses to inquiries about AFib and CIEDs, finding that ChatGPT Plus was the top performer with 84% and 88% respective appropriate response rates. Comprehensibility rates were consistently high across Google Bard, Bing Chat, and ChatGPT Plus (88% to 100%). However, relevant aspects were missing from many of the AFib and CIED responses from Google Bard (52% & 92% ), Bing Chat (60% & 88%), and ChatGPT Plus (24% & 52%).

Transformation Through Structured Reporting

Ready to realize the benefits of cardiovascular imaging structured reporting? Check out these quick and powerful Change Healthcare videos detailing the efficiency gains provided by structured reporting and what it takes to drive adoption.

A Milestone Study for Cardiac Strain Analysis

Us2.ai’s deep learning algorithm was able to interpret echo AI left ventricular strain images with similar accuracy as conventional measurements. Read all about this milestone study and its implications for echo strain access in EHJ-Digital Health.

The Resource Wire

• Advancing CAD Risk Assessments: When HeartFlow used its Plaque Analysis solution to analyze more than 11,000 CCTAs in the DECODE Study, the solution achieved 95% agreement with IVUS and led to changes in two out of every three patients’ treatment plans. See how HeartFlow Plaque Analysis can help you accurately assess your patients’ CAD risks and personalize their treatment.

• Bunkerhill Health’s Forbes Honors: Congratulations to Bunkerhill Health cofounders, David Eng and Nishith Khandwala, who were named to Forbes 30 under 30. Check out how they earned these honors in this Forbes profile.

• Accurately Measuring Heart Rate Variability: Heart rate variability measurement and analysis involves two critical elements – the ability to accurately discern the R wave in noisy environments, and using the correct analysis method for a given application. Check out how Monebo’s Kinetic HRV ECG Algorithm excels at both of these essential tasks.

• Experience the future of learning: Medtronic Academy 2.0 is here! Unlock your ultimate destination for structural heart medical education with the newly redesigned Medtronic Academy 2.0. Gain access to expert-led courses, webinars, and a wealth of resources to stay ahead in cardiovascular care. Visit now!

• Streamlining Cath Lab Hemodynamic Workflows: Is your hemodynamic solution keeping your cath lab efficient? Merge Hemo is a cath lab hemodynamic monitoring solution, providing a Best in KLAS user experience, while enhancing clinical workflows, automating data collection, and streamlining inventory management.